profit from every $100 of sales.
$0$100
Myriad Genetics
$5.67-1.22% today
-12.5% in 1 year
1-year low $2.861-year high $7.91
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Myriad Genetics sold, what it kept, and what it did with the cash.
Sales went from $678 million in 2022 to $825 million in 2025, with -$366 million of profit last year.
SalesProfit
Myriad Genetics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Myriad Genetics | No profit yet | ||
 Illumina | 38.2× · Expensive | ||
 Labcorp Holdings | 34.4× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Myriad Genetics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 678 | 753 | 838 | 825 | |
| 476 | 517 | 585 | 577 | |
| -124 | -145 | -88 | -68 | |
| -85 | -197 | -60 | -331 | |
| -112 | -263 | -127 | -366 | |
| -1.39 | -3.18 | -1.41 | -3.95 | |
| 70.2% | 68.6% | 69.9% | 69.9% | |
| -18.2% | -19.2% | -10.5% | -8.2% | |
| -16.5% | -35.0% | -15.2% | -44.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,199 | 1,147 | 1,028 | 707 |
| Cash | 57 | 132 | 102 | 150 |
| Total debt | 145 | 152 | 140 | 210 |
| Total liabilities | 313 | 363 | 327 | 339 |
| 886 | 783 | 701 | 368 | |
| 81 | 83 | 91 | 93 | |
| -10.5% | -21.9% | -11.3% | -52.6% | |
| -12.6% | -33.6% | -18.2% | -99.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -106 | -111 | -9 | 2 | |
| 45 | 73 | 30 | 27 | |
| -152 | -184 | -38 | -26 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 38 | 41 | 50 | 35 |
Valuation
- –
- 162.8×
- –
- 1.1×
- 0.7×
- –
- –
- -4.7%
- -67.3%
- 0.0%
Profitability
- 69.9%
- -8.2%
- -44.4%
- -40.3%
- -69.7%
- -24.0%
- -109.1%
- -59.4%
- -70.6%
- 12.8%
Growth
- +6.7%
- –
- +64.1%
- –
- +4.7%
Financial health
- –
- 0.63
- 31.4%
- -27.8×
- 2.40
- 2.19
- 1.23
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 952
Bottom 16%of 877
Bottom 34%of 871
Bottom 20%of 988
What analysts expect
- Average price target
- $6.00
- Range
- $6.00 – $6.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.09 | -0.06 | −50.0% |
| Feb 23, 2026 | 0.04 | -0.02 | +300.0% |
| Nov 3, 2025 | -0.13 | -0.01 | −1,200.0% |
| Aug 5, 2025 | 0.05 | -0.01 | +600.0% |
| May 6, 2025 | -0.03 | -0.05 | +40.0% |
| Feb 24, 2025 | 0.03 | 0.03 | +0.0% |
| Nov 7, 2024 | 0.06 | 0.02 | +215.8% |
| Aug 6, 2024 | 0.05 | 0.01 | +509.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
57No pass
Philip Fisher
27No pass
Peter Lynch
34No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
28No pass
Questions about Myriad Genetics
Is Myriad Genetics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Myriad Genetics AI analysis
What does Myriad Genetics do?
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It is in Medical - Diagnostics & Research.
Does Myriad Genetics pay a dividend?
No. Myriad Genetics does not pay a dividend at the moment.
Is Myriad Genetics stock halal?
No. Myriad Genetics does not pass our halal screen: its debt is 39% of its market value, at or above the 33% limit. How we check
How has Myriad Genetics stock done over the past year?
Down 12.5% over the past twelve months, to $5.67. It traded between $2.86 and $7.91 and is 28.3% below its high.
Who are Myriad Genetics's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Myriad Genetics's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.